The article you requested is
Branched Chain Amino Acid Treatment of Tardive Dyskinesia in Children and Adolescents.
Background: A series of studies had
demonstrated that deficient clearance of the large neutral amino
acid phenylalanine was associated with tardive dyskinesia (TD),
that the administration of the branched chain amino acids (BCAA)
significantly decreased TD symptoms over placebo, and that the
observed TD symptom reduction was significantly correlated with a
diminished availability of phenylalanine to the brain of adult
men with psychosis. As part of an initiative by the
National Institute of Mental Health to expand the testing of treatments that were successful in adults to children and adolescents, the present pilot study was undertaken to test whether the BCAA would also reduce TD symptoms in children and adolescents. A 2-week trial of the BCAA was thus conducted in 6 children and adolescents (age range, 10.5-16.5 years) for the treatment of TD symptoms.
Method: A clinical diagnosis of TD was made in
all subjects on the basis of a global score derived from the
Simpson Abbreviated Dyskinesia Rating Scale. Subjects were
videotaped for TD evaluation at baseline and after 1 and 2 weeks
of BCAA treatment given in the form of a drink
administered 3 times daily. TD symptom change over the trial period was evaluated by researchers blinded to the treatment status of the evaluation.
Results: TD symptom decreases were substantial in 5 of the 6 participants, ranging from 40% to 65%. Two of the subjects received an additional course of treatment, and further reductions in TD symptoms over those seen in the 2-week trial were observed.
Conclusion: The substantial symptom decrease and
tolerability observed suggest the use
of the BCAA formulation for the treatment of TD in children and adolescents and warrant further large-scale studies.